| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.7 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.7 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |